The risk of infections in psoriasis patients treated with biologics during the COVID-19 pandemic
For several years we have known that biologics for psoriasis are associated with an increased risk of infection – but what is the risk of respiratory tract infections and serious infections, like COVID-19? In this MEDtalk, Lara Van Der Schoot and Juul van den Reek, Radboud Institute for Health Sciences and Department of Dermatology, The Netherlands, discuss the risk of COVID-19, and whether there is a differential risk of infections between the biologics targeting different interleukins.
Få tilgang til artikkelen
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.